Testing a new medicine (galegenimab) to find out if it is effective for a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

• Age >/= 60 years at time of signing Informed Consent Form;
• Visual acuity: best-corrected visual acuity (BCVA) letter score >/= 24 letters (Snellen equivalent of 20/320 or better). If the study eye BCVA letter score is >/= 69 letters (Snellen equivalent of 20/40 or better), the non-study eye must have a BCVA letter score of >/= 44 letters (Snellen equivalent of 20/125 or better);
• Well-demarcated area of GA secondary to AMD with no evidence of prior or active choroidal neovascularization (CNV) in either eye.

Ocular Exclusion Criteria, Study Eye:

• History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD;
• Previous laser photocoagulation or ITV anti-vascular endothelial growth factor (anti-VEGF) for CNV, diabetic macular edema, retinal vein occlusion, or proliferative diabetic retinopathy.

Ocular Exclusion Criteria, Both Eyes:

• GA in either eye due to causes other than AMD;
• Active uveitis and/or vitritis (grade trace or above) in either eye;
• Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye;
• Retinal pigment epithelium (RPE) tear that involves the macula in either eye;
• Previous participation in interventional clinical trials for GA or dry AMD, except for vitamins and minerals, regardless of the route of administration (i.e., ocular or systemic) within the last 6 months.